CompletedPHASE1, PHASE2NCT00742963

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ImmunoGenesis
Principal Investigator
Kristen Ganjoo, MD
Stanford University
Intervention
TH-302(drug)
Enrollment
107 target
Eligibility
18 years · All sexes
Timeline
20082013

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00742963 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma

← Back to all trials